The Fund Built to Turn UW Lab Coats Into Cap Tables

The University of Washington has quietly become one of America's most productive startup factories. Since 1990, its labs have spun out roughly 260 companies. Those companies have raised close to $8 billion, and about 60 percent of that came in just the last five years. Somewhere in the last decade, the UW network produced an estimated ten unicorns - Turi, later bought by Apple; HashiCorp, later a $16 billion IPO; Sana Biotechnology; Lyell Immunopharma. The research was in Seattle. The returns, mostly, went to Sand Hill Road.

Ken Horenstein noticed. A third-generation Husky who went on to invest at Microsoft's corporate venture arm, he kept seeing the same pattern: a breakthrough leaves a UW building, gets funded by someone three states away, and becomes another city's success story. In 2021 he started Pack Ventures to close that gap - a Seattle pre-seed and seed fund built to write the first check into companies coming out of the University of Washington.

The firm's own description is blunt about the timing it wants: "Day-zero investors in research-led startups creating the future." Day zero is the pitch. Most funds wait for traction, a deck, a data room. Pack aims to be in the room before any of that exists.

01 / THE THESISA university as deal flow

Most venture firms sell founders on a network. Pack sells them on a place. Its entire sourcing engine is the University of Washington ecosystem - students, faculty, researchers, and alumni - and it has made that focus official. In 2024 the firm signed a memorandum of understanding with the university and CoMotion, UW's innovation and tech-transfer arm, naming Pack a "preferred venture partner." That designation is unusual, and it is hard for a rival fund to copy.

The model is not new in the abstract. Stanford, MIT, Berkeley, Michigan, and Harvard all have funds and programs tuned to campus innovation. What Horenstein has argued is that the Pacific Northwest lacked one - that despite UW's output, there was no fund built to systematically catch it at the earliest stage. Pack is his attempt to be the first.

02 / THE NUMBERSA $5M test, then a $30M sequel

Pack's first fund was deliberately small. It raised about $5 million from more than 80 investors and spread it across 26 companies in life sciences, software, and healthcare, with individual checks running from $25,000 to $200,000. Horenstein calls it a proof-of-concept - a way to prove the sourcing worked and the relationships held before asking anyone for real scale.

The sequel is bigger. Fund II targets $30 million and raises the ceiling on checks to as much as $750,000, letting Pack lead or anchor rounds rather than just ride along. It is structured as a 506(c) offering, which matters more than it sounds: that designation lets the firm openly market the fund and accept smaller individual commitments - part of a deliberate push to bring first-time investors into an asset class most of them have never had access to.

Where UW's edge shows up · illustrative signals of ecosystem scale

UW spinouts

~260

Capital raised

~$8B

Fund I bets

26

Unicorns/decade

~10

03 / THE PORTFOLIOLegal AI, space junk, designer proteins

The portfolio reads like a spread bet on the next decade of hard science. Supio builds legal AI that helps personal-injury firms surface case insights faster. TurionSpace works on space sustainability and national-security capability gaps - the unglamorous problem of tracking and clearing what's already in orbit. ArchonBio is developing a class of computationally designed biologic drugs. And Monod Bio, a spinout from UW Medicine's Institute for Protein Design, has raised $25 million and grown to a 26-person operation in Seattle's South Lake Union.

There is a through-line. These are companies where the science is the moat, where the founding team often came straight out of a lab, and where a generalist seed fund might not know how to underwrite the risk. Pack's bet is that proximity to the research is itself an edge.

04 / THE PEOPLEThe venture nerd and his co-founder

Horenstein describes himself as a "self-described venture nerd," and the label fits the mission: much of what he talks about is demystifying how venture actually works so that more people - founders and investors alike - can participate. He runs the firm as Founder and General Partner alongside co-founder Ti Zhao, a serial entrepreneur, with a small team of around 15 supporting a portfolio that spans software and the life sciences.

The values the firm names are straightforward - founders first, community-driven, collaborative - but the interesting part is who Pack counts as its community. It is not only the founders it funds. It is also the accredited investors it is coaxing into venture for the first time, many of them with UW ties of their own. In Horenstein's framing, widening the base of who backs startups is the second half of the same job as widening who gets funded.

05 / THE MARKETWhere Pack fits

Seattle is not short on venture capital - Madrona, Founders Co-op, and Ascend all invest early - but Pack occupies a narrower slot than any of them. It is not trying to be a generalist regional fund. It is trying to be the default first call for anyone spinning a company out of the University of Washington, closer in spirit to Berkeley's The House Fund or the campus vehicles at Stanford and MIT than to a traditional Sand Hill shop.

That focus is both the strength and the constraint. A fund tied to one university lives and dies on that university's output and on staying the preferred partner. Pack has bet that UW's research volume - all those spinouts and all that capital - is deep enough to sustain a fund built entirely around it. Fund I suggested the deal flow is real. Fund II is the test of whether it scales.

For a founder still in a UW lab, the pitch is simple: someone will fund you before you have a company, help you incorporate it, and stay local while you build. For an investor who never thought venture was open to them, the pitch is nearly the same - a seat at day zero. Whether that turns into the returns the region has been exporting for years is the open question. The research, at least, is not the bottleneck.